SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--Fluidigm Corporation today announced that the Cancer Research UK Centre for Genetic Epidemiology, University of Cambridge, based at Strangeways Research Laboratory in the United Kingdom, has purchased the company’s EP1 System to conduct cancer research and disease association studies. The Fluidigm EP1 system combines the efficiencies of integrated fluidic circuit (IFC)-based high-throughput genotyping in a desktop-sized configuration, with a very affordable system price.
